Cantor Fitzgerald Keeps $15 PT on Roivant Sciences (ROIV), 'Keep It Top Of Mind, Highly Anticipated Phase 3 AD Data Coming 1H23'
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $15.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
